AJP - Endo Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 284: E1156-E1161, 2003. First published February 11, 2003; doi:10.1152/ajpendo.00427.2002
0193-1849/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
284/6/E1156    most recent
00427.2002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stefan, N.
Right arrow Articles by Tataranni, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stefan, N.
Right arrow Articles by Tataranni, P. A.
Vol. 284, Issue 6, E1156-E1161, June 2003

Elevated plasma nonesterified fatty acids are associated with deterioration of acute insulin response in IGT but not NGT

Norbert Stefan, Michael Stumvoll, Clifton Bogardus, and P. Antonio Tataranni

Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016

High concentrations of nonesterified fatty acids (NEFA) are a risk factor for developing type 2 diabetes in Pima Indians. In vitro and in vivo, chronic elevation of NEFA decreases glucose-stimulated insulin secretion. We hypothesized that high fasting plasma NEFA would increase the risk of type 2 diabetes by inducing a worsening of glucose-stimulated insulin secretion in Pima Indians. To test this hypothesis, fasting plasma NEFA concentrations, body composition, insulin action (M), acute insulin response (AIR, 25-g IVGTT), and glucose tolerance (75-g OGTT) were measured in 151 Pima Indians [107 normal glucose tolerant (NGT), 44 impaired glucose tolerant (IGT)] at the initial visit. These subjects, participants in ongoing studies of the pathogenesis of obesity and type 2 diabetes, had follow-up measurements of body composition, glucose tolerance, M, and AIR. In NGT individuals, cross-sectionally, high fasting plasma NEFA concentrations at the initial visit were negatively associated with AIR after adjustment for age, sex, percent body fat, and M (P = 0.03). Longitudinally, high fasting plasma NEFA concentrations at the initial visit were not associated with change in AIR. In individuals with IGT, cross-sectionally, high fasting plasma NEFA concentrations at the initial visit were not associated with AIR. Longitudinally, high fasting plasma NEFA concentrations at the initial visit were associated with a decrease in AIR before (P < 0.0001) and after adjustment for sex, age at follow-up, time of follow-up, change in percent body fat and insulin sensitivity, and AIR at the initial visit (P = 0.0006). In conclusion, findings in people with NGT indicate that fasting plasma NEFA concentrations are not a primary etiologic factor for beta -cell failure. However, in subjects who have progressed to a state of IGT, chronically elevated NEFA seem to have a deleterious effect on insulin-secretory capacity.

beta -cell; insulin secretion; insulin sensitivity; diabetes; oral and intravenous glucose tolerance tests; normal glucose tolerance; impaired glucose tolerance


This article has been cited by other articles:


Home page
Diabetes CareHome page
G. Boden and M. Laakso
Lipids and Glucose in Type 2 Diabetes: What About the {beta}-Cell and the Mitochondria?: Response to Eldor and Raz
Diabetes Care, April 1, 2005; 28(4): 986 - 987.
[Full Text] [PDF]


Home page
Diabetes CareHome page
G. Boden and M. Laakso
Lipids and Glucose in Type 2 Diabetes: What is the cause and effect?
Diabetes Care, September 1, 2004; 27(9): 2253 - 2259.
[Full Text] [PDF]


Home page
Diabetes CareHome page
J. S. Pankow, B. B. Duncan, M. I. Schmidt, C. M. Ballantyne, D. J. Couper, R. C. Hoogeveen, and S. H. Golden
Fasting Plasma Free Fatty Acids and Risk of Type 2 Diabetes: The Atherosclerosis Risk in Communities study
Diabetes Care, January 1, 2004; 27(1): 77 - 82.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.